ASCO: Sotorasib Targets KRAS p.G12C-Mutated NSCLC
Objective response seen in 37.1 percent of patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.